PT  - JOURNAL ARTICLE
AU  - Ivo Stárek
AU  - Jirí Hoza
AU  - Petr Schalek
AU  - Renata Kellnerová
TI  - Erdosteine - A new drug in the treatment of chronic rhinosinusitis
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P2175
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P2175.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P2175.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - Introduction. Antiinflammatory macrolide antibiotics proved efficient in chronic rhinosinusitis (CRS). Since this medication is associated with potential side effects and the danger of development of resistent bacteria, alternative drugs are being sought.Objectives. Another drug exerting similar, cytokine-mediated antiinflammatory response is Erdosteine. However, it has not been tested in this diagnosis yet. In a prospective post-authorisation study we therefore assessed the efficacy of Erdosteine in patients with CRS.Methods. 60 patients with CRS were enrolled, with 33 and 27 of them being treated by Erdosteine 2x300 mg without (group I) and with topical steroid (group II), respectively, for 3 months. Outcome measures included Sinonasal Outcome Test (SNOT-22) and nasal endoscopic score (Levine-May).Results. The pre- and posttreatment SNOT-22 score in group I was 36 and 19, in group II 39 and 27, respectively. The nasal endoscopic score in group I was 2.55 and 1.29, in group II 2.02 and 1.30. In both groups the differences showed statistical significance.Conclusion. The results of our pilot study suggest Erdosteine treatment efficacy in CRS. Additional in vitro and clinical studies are required to determine its precise action.